Quarterly ResultAug 6, 2026, 07:32 AM
Nuvation Bio Q2 Revenue $31.7M; IBTROZI Sales $23.2M; Net Loss $62.8M
AI Summary
Nuvation Bio Inc. reported second quarter 2026 financial results, with total revenue of $31.7 million, including $23.2 million in net product revenue for IBTROZI, marking a 25% quarter-over-quarter increase. The company also announced positive updated long-term Phase 2 data for safusidenib and expanded its clinical program. Despite an increased net loss of $62.8 million, Nuvation Bio strengthened its balance sheet with $661.0 million in cash, cash equivalents, and marketable securities, further boosted by $36.5 million from a convertible senior notes offering.
Key Highlights
- Total revenue reached $31.7 million for Q2 2026.
- Net product revenue for IBTROZI was $23.2 million, reflecting 25% quarter-over-quarter growth.
- Approximately 85% of 160 new IBTROZI patient starts were TKI-naïve, a 30% QoQ growth.
- Cash, cash equivalents, and marketable securities stood at $661.0 million as of June 30, 2026.
- Secured an additional $36.5 million in net proceeds from convertible senior notes overallotment option in July 2026.
- Reported a net loss of $62.8 million, or $(0.18) per share, for Q2 2026.
Price Impact
More from NUVB